SUZHOU ZELGEN BIOPHARMACEUTICALS CO.,LTD.

Suzhou Zelgen Biopharmaceuticals Co.,Ltd.

688266

CNE100003RP1

Suzhou Zelgen Biopharmaceuticals Co Ltd is a China-based company mainly engaged in pharmaceutical manufacturing. The Company's main products include pharmaceuticals and pharmaceutical intermediates and raw materials. Its products are mainly applied in the fields of tumors, bleeding and blood diseases, immune inflammatory diseases and hepatobiliary diseases. The Company operates in the domestic market and overseas markets.

Employees

858

Sector

Pharmaceuticals

Calendar

24/10/2024 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

58.88CNY

Average target price

67.00CNY

Spread / Average Target

+13.79%

Consensus

Profit revisions

Estimate revisions

Annual profits - Rate of surprise

Company calendar

End-of-day quote Shanghai S.E. Other stock markets 19/09/2024			5-day change	1st Jan Change
58.88 ^CNY	-4.80%		-4.23%	+11.22%

09-09	Suzhou Zelgen Biopharmaceuticals' ZG006 Drug Demonstrates Efficacy in Treating Tumors	MT
08-23	Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	CI

Suzhou Zelgen Biopharmaceuticals' ZG006 Drug Demonstrates Efficacy in Treating Tumors	09-09	MT
Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	08-23	CI
Zelgen Biopharma's Thyroid Cancer Drug Gets Clinical, Pharmaceutical Registration Verification	08-13	MT
Suzhou Zelgen Biopharmaceuticals Gets Orphan Drug Designation for Lung Cancer Drug	08-09	MT
Zelgen Biopharmaceutical Gets Nod to Trial Advanced Hepatocellular Carcinoma Drug Combination	08-06	MT
Zelgen Biopharmaceutical's Phase II Trial of Gecaxitinib Hydrochloride Tablets Shows Positive Results	08-02	MT
Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-19	CI
Suzhou Zejing Topical Vitiligo Cream Gets NMPA's Nod for Clinical Trials	04-12	MT
Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	02-23	CI
Zelgen Biopharmaceuticals Grants Yuanda Life Unit Marketing Rights for Recombinant Human Thrombin	12-08	MT
Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	27/10/23	CI
Zelgen Biopharma’s Phase III Trial of Thyroid Cancer Treatment Yields Positive Results	19/09/23	MT
Suzhou Zelgen Biopharmaceuticals Co., Ltd.(XSSC:688266) added to S&P Global BMI Index	18/09/23	CI
Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	25/08/23	CI
Zelgen Biopharmaceuticals Gets Nod for China Clinical Trial of Solid Tumor Drug	31/07/23	MT
Apeloa Pharma Forms Strategic Drug Alliance With Zelgen Biopharma	13/06/23	MT
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	21/04/23	CI
Suzhou Zelgen Biopharmaceuticals Co., Ltd. announced that it has received CNY 1.45529 billion in funding	20/04/23	CI
Zelgen Biopharma Gets Nod for Clinical Trials of Tumor Drug	19/04/23	MT
Zelgen Biopharmaceuticals Wins FDA Nod to Trial Lung Cancer Drug	11/04/23	MT
Zelgen Biopharmaceuticals Certified as High-Tech Enterprise in China	03/03/23	MT
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	13/10/22	CI
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	18/08/22	CI
Zelgen Biopharma Wins Nod to Launch Clinical Trial of Tumor Treatment	17/08/22	MT
Suzhou Zelgen Biopharmaceuticals Co., Ltd.(SHSE:688266) dropped from Shanghai Stock Exchange Health Care Sector Index	10/06/22	CI

Suzhou Zelgen Biopharmaceuticals Co.,Ltd.

Equities